Wegovy (Semaglutide) Denied by Insurance: Full Appeal

Wegovy (semaglutide 2.4 mg) is a once-weekly injectable GLP-1 receptor agonist developed by Novo Nordisk, FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition. Unlike Ozempic (semaglutide 1.0 mg for type 2 diabetes), Wegovy is formulated and FDA-indicated exclusively for the treatment of obesity. It produces average weight loss of 15% of body weight in clinical trials — more than any other non-surgical weight management treatment previously available. Despite this clinical evidence and its status as an FDA-approved prescription medication for a serious chronic disease, Wegovy is denied by insurance more often than almost any other medication. This article explains why — and what you can do about it.

Obesity Is a Chronic Disease — and Still Largely Excluded

The foundation of most Wegovy denials is a policy exclusion, not a clinical determination. Most employer-sponsored health plans include explicit language excluding coverage for "weight loss drugs," "anti-obesity medications," or "drugs used primarily for cosmetic purposes." These exclusions predate Wegovy and were written in an era when weight management drugs were less effective, less safe, and not considered serious medical therapy.

The medical community has moved decisively in the opposite direction. The American Medical Association recognized obesity as a chronic disease in 2013. The FDA granted Wegovy full approval as a treatment for obesity in 2021. Major professional societies — including the Obesity Society, AACE, and AHA — now treat obesity pharmacotherapy as standard clinical care alongside dietary intervention. Yet employer plan documents written years ago still govern coverage decisions, creating a profound gap between clinical standards and insurance coverage.

Why Employers Exclude Coverage

Cost is the primary reason. Wegovy costs approximately $1,300–$1,400 per month at list price (before discounts and rebates). Employers covering tens of thousands of employees worry that if they add anti-obesity medication coverage, a large proportion of eligible employees will enroll, creating enormous cost exposure. Until very recently, most actuarial analyses did not credit the downstream savings from reduced obesity-related conditions (lower rates of T2D, hypertension, sleep apnea, joint disease, and cardiovascular events), making the cost-benefit calculation appear unfavorable.

ERISA self-funded plan discretion. The Employee Retirement Income Security Act (ERISA) gives employers who self-fund their health plans broad discretion to define what is covered and what is excluded. ERISA-governed plans are largely exempt from state insurance mandates, which means state laws requiring obesity drug coverage do not apply to the majority of large employer plans. Insurers administering these plans must follow employer benefit documents, not just medical evidence.

Medicare historical exclusion. Medicare Part D has historically excluded coverage for drugs used for weight gain or loss — though the SELECT trial data showing that semaglutide reduces major cardiovascular events in patients with obesity and cardiovascular disease created a pathway for limited Medicare coverage under the cardiovascular risk reduction indication.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior Authorization Requirements When Coverage Exists

When an employer plan or individual/small group plan does cover Wegovy, prior authorization is required and typically includes:

• BMI measurement from a recent clinical visit (typically ≥30, or ≥27 with a documented comorbidity)
• Documentation of the qualifying comorbidity (hypertension, T2D, dyslipidemia, or obstructive sleep apnea) if BMI is 27–29.9
• Documentation of prior behavioral weight management intervention (diet counseling, lifestyle program) — some plans require failure of a 3–6 month structured program
• Prescriber attestation that Wegovy is being used as part of a comprehensive weight management plan that includes diet and exercise

How to Appeal a Wegovy Denial

Review your plan document for the exact exclusion language. Request a copy of your Summary Plan Description (SPD) and any clinical coverage criteria. Some plans exclude "weight loss drugs" but cover medications for "obesity-related comorbidities" — which could include Wegovy prescribed primarily for hypertension or cardiovascular risk reduction in a patient with comorbid obesity.

Reframe the primary diagnosis. If your prescribing physician documented Wegovy for obesity AND a qualifying comorbidity such as hypertension, prediabetes, or sleep apnea, the appeal should emphasize the comorbidity treatment angle. An appeal that frames Wegovy as treatment for cardiovascular risk reduction (supported by the SELECT trial showing semaglutide reduces MACE by 20% in patients with cardiovascular disease and obesity) is a stronger argument than one framed as "weight loss."

Document the clinical evidence. Include the STEP 1 and STEP 2 clinical trial results showing 15% average weight loss with Wegovy, the cardiovascular outcomes data from the SELECT trial, and references to American Heart Association and Obesity Society guidelines supporting pharmacotherapy for obesity as a chronic disease.

Obtain a comprehensive letter of medical necessity. Your physician should write a letter that:

1. Establishes obesity as a chronic disease diagnosis (ICD-10 E66) with specific health consequences for you
2. Documents your BMI and qualifying comorbidities
3. Describes prior weight management interventions (diet, exercise, behavioral counseling) and their insufficient results
4. Explains why Wegovy is medically necessary for your specific health risks
5. Articulates the expected clinical benefits beyond weight loss (blood pressure reduction, improved A1C, reduced cardiovascular risk)

Challenge blanket exclusions as clinically outdated. While employer plan exclusions are difficult to override legally, a well-documented appeal can sometimes succeed — particularly if the plan's exclusion language does not precisely cover an FDA-approved prescription medication for a recognized chronic disease. Some exclusion language written decades ago refers to "appetite suppressants" or "over-the-counter weight loss products" and may not technically apply to a prescription GLP-1 receptor agonist.

If Medicare denied: Determine whether you have established cardiovascular disease. For Medicare patients with obesity and documented CVD (coronary artery disease, stroke, peripheral artery disease), Wegovy coverage through Part D may be available under the cardiovascular risk reduction indication following the SELECT trial results. Your cardiologist's documentation of CVD history is key to this pathway.

Patient Assistance Programs

Novo Nordisk offers the NovoCare Wegovy Patient Assistance Program for qualifying uninsured or underinsured patients. Copay savings cards are also available for commercially insured patients with coverage. Visit novocare.com/wegovy or call 1-833-NOVO-411 (1-833-668-6411).

Given Wegovy's high list price, many patients who are denied coverage should explore the patient assistance program regardless of plan coverage status, as copay programs can dramatically reduce the out-of-pocket burden for covered patients as well.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?